Hepatopancreatobiliary Carcinoma

subtype

Identifier: CI-CAN-00002859
Entity page: /cancer/hepatopancreatobiliary-carcinoma ↗
Edges: 5,843

Neighbours: 15 genes26 drugs10 trials
Drawn: 51 of 51 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Hepatopancreatobiliary Carcinoma approved for …APPROVED_FORderived26 of 26show fewer
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Pancreatic Adenocarcinoma	—	approved	Pancreatic Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for	Futibatinib

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

FGFR2 Fusion Infigratinib0 active / 5 trials
Curatedlevel Asensitivity· support 3civicObservedFGFR2 altered in 3% (41 / 1,370 cases)no approval record in this cancercontext: Cholangiocarcinoma
FGFR2 Fusion Infigratinib0 active / 5 trials
Curatedlevel Asensitivity· support 3civicObservedFGFR2 altered in 3% (41 / 1,370 cases)no approval record in this cancercontext: Cholangiocarcinoma
IDH1 R132 IvosidenibFDA US 2018-07-203 active / 6 trials
Curatedlevel Asensitivity· support 1civicObservedIDH1 altered in 10% (141 / 1,370 cases, largest of 4 cohorts)Regulatoryapproved for Cholangiocarcinomacontext: Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-174 active / 12 trials
Curatedlevel Asensitivity· support 1civicObservedFGFR2 altered in 3% (41 / 1,370 cases)Regulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
FGFR2 Fusion PemigatinibFDA US 2020-04-174 active / 12 trials
Curatedlevel Asensitivity· support 1civicObservedFGFR2 altered in 3% (41 / 1,370 cases)Regulatoryapproved for Cholangiocarcinoma (2 approval records)context: Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma
BRCA2 Loss-of-function OlaparibFDA US 2017-08-1713 active / 21 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 2.1% (29 / 1,370 cases)Regulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
BRCA1 Loss-of-function OlaparibFDA US 2017-08-1713 active / 21 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Pancreatic Adenocarcinomacontext: Pancreatic Adenocarcinoma
NRG1 Fusion Zenocutuzumab-zbco0 active / 1 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for NRG1 in this cancerno approval record in this cancercontext: Pancreatic Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Hepatopancreatobiliary Carcinoma altered in cohorts of …ALTERED_INderived15 of 420show all (up to 200)
← altered in cohorts of	HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL	—	—	Cholangiocarcinoma	1	Observed	gdc	graph →

Hepatopancreatobiliary Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 247show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 283 trials (94 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	283	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 182 trials (12 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	182	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 151 trials (67 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	151	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 133 trials (68 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	133	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 127 trials (53 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	127	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 119 trials (42 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	119	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 102 trials (33 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 100 trials (38 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	100	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 92 trials (61 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	92	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 90 trials (41 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	90	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 86 trials (27 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	86	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 76 trials (47 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	76	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 74 trials (24 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	74	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 64 trials (28 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 63 trials (30 active) · roll-up of the cancer and its descendants	—	—	Hepatopancreatobiliary Carcinoma	63	Observed	clinicaltrials	graph →

Hepatopancreatobiliary Carcinoma studied in …STUDIED_INderived10 of 5,150show all (up to 200)
→ studied in	NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 5,150 trials mapped (1,728 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01824875Phase 2 · completed Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 5,150 trials mapped (1,728 active)	—	—	Pancreatic Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 5,150 trials mapped (1,728 active)	—	—	Exocrine Pancreas Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 5,150 trials mapped (1,728 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 5,150 trials mapped (1,728 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 5,150 trials mapped (1,728 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped ALIAS · 5,150 trials mapped (1,728 active)	—	—	Pancreatic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05176223Phase 2 · completed 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer · condition mapped CURATED_BROADER · 5,150 trials mapped (1,728 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 5,150 trials mapped (1,728 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06605664Phase 2 · recruiting Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab · condition mapped ONTOLOGY_EXACT · 5,150 trials mapped (1,728 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →